CDMO

Alcami Announces CEO Transition

Retrieved on: 
Monday, June 5, 2023
Pepperdine University, Partner, The Crane Group Companies, MBA, Strata Skin Sciences, Bucknell University, Organization, CDMO, Retirement, Entrepreneurship, Growth, SKNV, Management, Stiefel

Bill Humphries to succeed Patrick Walsh as CEO effective June 5th, 2023

Key Points: 
  • Bill Humphries to succeed Patrick Walsh as CEO effective June 5th, 2023
    WILMINGTON, N.C., June 5, 2023 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the retirement of Patrick Walsh and the subsequent appointment of Bill Humphries as the next CEO, effective June 5th, 2023.
  • Prior to Alcami, Humphries' executive leadership roles included CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals.
  • He further commented, "I feel fortunate that Pat is remaining in the Alcami family, and the opportunity to work with the Alcami team, Pat, our outstanding Board members and Partners provides me every confidence in the future growth of Alcami."
  • With this transition, we are delighted to welcome Bill Humphries as our new CEO.

Ajinomoto Integrates R&D Sites in Japan and Korea with Genedata Bioprocess

Retrieved on: 
Monday, June 5, 2023
Vaccine, Therapy, Big data, Amino acid, CDMO, Architecture, B cell, Automation, Fine chemical, Ajinomoto, Genedata

BASEL, Switzerland and TOKYO, June 5, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, and Ajinomoto, a leading multinational supplier of cell culture media as well as development and manufacturing services (CDMO), today announced that Ajinomoto has successfully rolled out Genedata Bioprocess® to its Korean sites, Ajinomoto Genexine, in line with Ajinomoto's transformational R&D digitalization strategy.

Key Points: 
  • "Genedata Bioprocess has been quickly adopted by our Japanese teams to streamline and accelerate our media development activities," said Hiroyuki Mise, General Manager of Biopharma Solutions Group, Amino Acids Department of Ajinomoto.
  • After the successful deployment in Japan, we have now expanded the use of Genedata Bioprocess to our Korea-based teams to facilitate cross-site projects, resulting in significantly more efficient operations in our joint projects.
  • Ajinomoto uses Genedata Bioprocess as their central data backbone to streamline cell culture media development and production operations, including in regulated environments.
  • "I am delighted to see that Ajinomoto is expanding the usage of Genedata Bioprocess across its Asian development and manufacturing sites, which is how we envision our platform to be used," said Othmar Pfannes, Ph.D., CEO of Genedata.

AGC Biologics Introduces AGCellerate, Offering Fast Timelines, Fixed Pricing and Guaranteed Product Quantity

Retrieved on: 
Monday, June 5, 2023
Health, Genetics, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, Immortalised cell line, GMP, Plasmid, Hook effect, Food and Drug Administration, AGC, EMA, CDMO, Patient, European Medicines Agency, FDA, Zenith Contract Services, Food, Fine chemical, Vaccine, Pharmaceutical industry

AGCellerate offers guaranteed amounts at fixed timelines and costs – accelerating projects through development and into clinical phases.

Key Points: 
  • AGCellerate offers guaranteed amounts at fixed timelines and costs – accelerating projects through development and into clinical phases.
  • The new program offers support to biologics projects using monoclonal antibodies (mAbs), lentiviral vectors, adeno-associated vectors and Plasmid DNA (pDNA) material.
  • Drawing on 30 years of scientific expertise, the AGCellerate program offers a templated approach to maximize speed and product deliverables.
  • That is at the center of everything we strive to do at AGC Biologics,” said JB Agnus, Chief Business Officer, AGC Biologics.

Signing of Exclusive Distributorship Agreement With EVERZOM

Retrieved on: 
Friday, June 2, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, GMP, SPI, University, Head, Exosome, MicroRNA, Multimedia, Cell, SAS, Protein, CDMO, Engineering, Quality control, Pharmaceutical industry

Summit Pharmaceuticals International (Head Office: Chiyoda-ku, Tokyo; Chief Executive Officer: Katsuya Okuyama; hereinafter “SPI”) has signed an exclusive distributorship agreement in Japan with EVERZOM, SAS*.

Key Points: 
  • Summit Pharmaceuticals International (Head Office: Chiyoda-ku, Tokyo; Chief Executive Officer: Katsuya Okuyama; hereinafter “SPI”) has signed an exclusive distributorship agreement in Japan with EVERZOM, SAS*.
  • (hereinafter “EVERZOM”), a France-based company providing exosome manufacturing service.
  • EVERZOM is a Contract Development and Manufacturing Organization (CDMO) specialized in exosomes, which spun out from the CNRS Laboratory at the University of Paris Cité in 2019.
  • SPI is committed to working with EVERZOM to further promote and develop exosome research in Japanese market.

EQS-News: Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease

Retrieved on: 
Friday, June 2, 2023
BIO, Therapy, IgG4-related ophthalmic disease, Senior, CMC, Geographic atrophy, ATMP, AAV, CDMO, Eye, Patient, BD, Vaccine, Pharmaceutical industry

Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.

Key Points: 
  • Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.
  • Dr. Katie Binley, Chief Scientific Officer of Ikarovec, said: “We are delighted to collaborate with Rentschler Biopharma on our lead program.
  • Dr. Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, added: “With Rentschler Biopharma’s ATMP offering, we aim to address an important gap in specific support for innovative, early-stage cell and gene therapy programs.
  • Ikarovec and its novel candidate are a perfect fit for our services.

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease

Retrieved on: 
Thursday, June 1, 2023
BIO, Therapy, IgG4-related ophthalmic disease, Senior, CMC, Geographic atrophy, ATMP, AAV, CDMO, Eye, Patient, NORWICH, BD, Vaccine, Pharmaceutical industry

Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.

Key Points: 
  • Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.
  • Dr. Katie Binley, Chief Scientific Officer of Ikarovec, said: “We are delighted to collaborate with Rentschler Biopharma on our lead program.
  • Dr. Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, added: “With Rentschler Biopharma’s ATMP offering, we aim to address an important gap in specific support for innovative, early-stage cell and gene therapy programs.
  • Ikarovec and its novel candidate are a perfect fit for our services.

Lifecore Biomedical Reports Third Quarter Fiscal Year 2023 Results

Retrieved on: 
Thursday, June 1, 2023
Borrowing base, FINANCIAL, Bank statement, HA, Fermentation, Sale, EBITDA, CDMO, Alcon, Salad, Video game

CHASKA, Minn., June 01, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), reported results for the fiscal 2023 third quarter ended February 26, 2023.

Key Points: 
  • CHASKA, Minn., June 01, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), reported results for the fiscal 2023 third quarter ended February 26, 2023.
  • In combination with the sale of our remaining Curation Foods segment business in early April, Lifecore is beginning a new chapter as a stand-alone CDMO.
  • The product of these advancements will be visible in fiscal fourth quarter performance with a sequential step up in Lifecore's segment adjusted EBITDA that approximates a doubling of fiscal third quarter results."
  • CONSOLIDATED FISCAL THIRD QUARTER 2023 RESULTS:
    Fiscal third quarter 2023 results compared to fiscal third quarter 2022 are as follows:

Fujifilm Life Sciences to Showcase Innovative and Comprehensive Solutions Supporting Advanced Therapies at BIO 2023

Retrieved on: 
Thursday, June 1, 2023
Ionization, Vaccine, BIO, Medicine, Therapy, IPSC, Education, Lipid, Boston Convention and Exhibition Center, Traffic barrier, Research, Hasegawa, Fujifilm Diosynth Biotechnologies, Cell, Development, Fujifilm, CDMO, CGMP, Patient, Antibody, Drug discovery, Exhibition, Convention center, Fine chemical, Pharmaceutical industry, Management

“Fujifilm Life Sciences is proud to join BIO 2023 where we will showcase our group company solutions and explore new partnerships with today's leading research organizations and biotech companies.

Key Points: 
  • “Fujifilm Life Sciences is proud to join BIO 2023 where we will showcase our group company solutions and explore new partnerships with today's leading research organizations and biotech companies.
  • Our business portfolio now includes cell culture solutions, research tools such as reagents, investigational drug development, drug delivery solutions, cell therapy development, quality control testing solutions, as well as Bio-CDMO.
  • Through our comprehensive offering, we are uniquely positioned to support and accelerate bringing new therapies to patients in need,” said Yutaka Yamaguchi, corporate vice president and general manager, Life Sciences Business Division, FUJIFILM Corporation, and chairman and chief executive officer, FUJIFILM Irvine Scientific, Inc.
  • Learn more about Fujifilm Life Sciences: https://lifesciences.fujifilm.com/

Freudenberg Medical Utilizes VR Training in Catheter Manufacturing

Retrieved on: 
Thursday, June 1, 2023
Medical Devices, Manufacturing, Other Manufacturing, Health, Pharmaceutical, Medicine, Lean manufacturing, VP-60, Multimedia, Catheter, VR, CDMO, Medical device, Video game

Freudenberg Medical , a global CDMO for finished medical devices, components, and minimally invasive solutions, has implemented virtual reality training for employees working in catheter production at operations in Ireland and the United States.

Key Points: 
  • Freudenberg Medical , a global CDMO for finished medical devices, components, and minimally invasive solutions, has implemented virtual reality training for employees working in catheter production at operations in Ireland and the United States.
  • The VR training program ensures employees have the necessary skills to meet the high-quality standards in catheter manufacturing for customers worldwide.
  • Now after three days of VR training operators are able to hit takt time which increases manufacturing efficiency by a multiple.
  • “Against the backdrop of global supply chain disruptions in recent years, implementing the VR training was particularly beneficial.”
    After a successful rollout in Ireland, Freudenberg Medical is currently implementing the program at a catheter production site in the U.S.

BioCentriq® Launches LEAP™ Advanced Therapy Platform with Proven Assets and Expertise that Help Early-Stage BioTech Companies Reach Patients in Record Time

Retrieved on: 
Thursday, June 1, 2023
Pressure, CDMO, International Society, ISCT, Cell, Pharmaceutical industry

NEWARK, N.J., June 1, 2023 /PRNewswire/ -- BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy launched their new LEAP™ Advanced Therapy Platform today at the 29th International Society for Cell & Gene Therapy (ISCT) annual event.

Key Points: 
  • NEWARK, N.J., June 1, 2023 /PRNewswire/ -- BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy launched their new LEAP™ Advanced Therapy Platform today at the 29th International Society for Cell & Gene Therapy (ISCT) annual event.
  • "In the current economic environment, biotech companies with promising candidates are under greater pressure than ever to demonstrate results quickly," said Haro Hartounian, Ph.D. and CEO and Founder of BioCentriq.
  • "The LEAP™ platform is designed to help early-stage biotech companies prioritize speed in a very calculated and conscientious manner without compromising quality or introducing unnecessary risks."
  • The LEAP™ advanced therapy platform utilizes pre-existing assets and expertise to reduce process development and scale-up timelines by up to 75%.